Insulin degludec 100 U/mL — Competitive Intelligence Brief

Insulin degludec 100 U/mL (Insulin degludec 100 U/mL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting basal insulin. Area: Diabetes.

marketed Long-acting basal insulin Insulin receptor Diabetes Small molecule

Target snapshot

Insulin degludec 100 U/mL (Insulin degludec 100 U/mL) — Sanofi. Insulin degludec is a long-acting basal insulin that binds to the insulin receptor to promote glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin degludec 100 U/mL TARGET	Insulin degludec 100 U/mL	Sanofi	marketed	Long-acting basal insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting basal insulin class)

1. Sanofi · 12 drugs in this class
2. Novo Nordisk A/S · 3 drugs in this class
3. Life for a Child Program, Diabetes Australia · 1 drug in this class
4. Massachusetts General Hospital · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Providence Health & Services · 1 drug in this class
7. Rabin Medical Center · 1 drug in this class
8. Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class
9. University Hospital Tuebingen · 1 drug in this class
10. Gan and Lee Pharmaceuticals, USA · 1 drug in this class